Background:  Biliverdin Reductase (BVR) catalyzes the final step in the heme metabolic pathway, the reduction of biliverdin IX{alpha} to bilirubin, with the concomitant oxidation of a NADH or NADPH cofactor. The enzyme remains unique among all biological catalysts described to date in having a dual pH/cofactor-dependent activity profile. Human biliverdin reductase (hBVR) has been recently shown to be a Ser/Thr/Tyr kinase in the MAPK insulin/insulin-like growth factor 1 (IGF1)-signaling cascade. BVR together with its substrate, biliverdin, and product, bilirubin, have recently been revealed to be important players in cellular signal transduction pathways, gene expression and oxidative response. These features make BVR unusually interesting and unique among all enzymes characterized to date.

Description: Rabbit polyclonal to BLVRA

Immunogen: KLH conjugated synthetic peptide derived from BLVRA

Specificity:  ·Reacts with Human, Mouse, Pig and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 33 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.